Last reviewed 2026-04-23 · How we verify

Triamcinolone + Nepafenac

Triamcinolone reduces inflammation via glucocorticoid receptor activation while nepafenac inhibits prostaglandin synthesis through COX inhibition, providing combined anti-inflammatory and analgesic effects.

Triamcinolone reduces inflammation via glucocorticoid receptor activation while nepafenac inhibits prostaglandin synthesis through COX inhibition, providing combined anti-inflammatory and analgesic effects. Used for Postoperative ocular inflammation and pain following cataract surgery, Ocular inflammation associated with ophthalmic procedures.

At a glance

Mechanism of action

Triamcinolone is a corticosteroid that suppresses inflammatory cytokines and immune cell activation by binding glucocorticoid receptors. Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing prostaglandin production. Together, they provide dual anti-inflammatory action for ocular conditions.

Approved indications

• Postoperative ocular inflammation and pain following cataract surgery
• Ocular inflammation associated with ophthalmic procedures

Common side effects

• Ocular irritation
• Corneal effects
• Increased intraocular pressure
• Conjunctival hyperemia

Key clinical trials

• The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
• Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema (PHASE3)
• Dropless vs. Standard Drops Contralateral Eye Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.